Validation of the collapsed-cone superposition for whole-body patient-specific dosimetry in [177Lu]Lu-PSMA-617 radionuclide therapy. [PDF]
Terro A +7 more
europepmc +1 more source
IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. [PDF]
Vuleta Nedic K +9 more
europepmc +1 more source
Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade. [PDF]
Haugh KN, Sanwick AM, Chaple IF.
europepmc +1 more source
Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape. [PDF]
Weller M +9 more
europepmc +1 more source
Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors. [PDF]
Santo G +3 more
europepmc +1 more source
Targeted radionuclide therapy for patients with central nervous system metastasis: Overlooked potential? [PDF]
Le Rhun E +10 more
europepmc +1 more source
SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. [PDF]
Hasenauer N +9 more
europepmc +1 more source
Peptide Receptor Radionuclide Therapy in Patients with Advanced, Recurrent or Progressive Meningioma: An Updated Systematic Review and Meta-Analysis. [PDF]
Muoio B +6 more
europepmc +1 more source
Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma. [PDF]
Kunte SC +11 more
europepmc +1 more source

